The Drug-Induced Respiratory Disease Website

III. Myocardial ischemia - Coronary artery disease

III.a Coronary artery disease (acute) - Myocardial ischemia/infarction

XI. Pulmonary vasculopathies

XI.a Pulmonary arterial hypertension

XII. Pericardial involvement

XII.n Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XIV. Pleural involvement

XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)

XVI. Hemorrhage - Bleeding - Hematoma(s)

XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)

XVI. Hemorrhage - Bleeding - Hematoma(s)

XVI.i Hemoptysis

XVIII. Aortic involvement

XVIII.c Arterial (aorta, limb) vasoconstriction and/or ischemia, acute

XX. Vasculitis

XX.d Vasculitis, pulmonary (w/wo AH), extrathoracic, or systemic: ANCA-positive

XXVIII. Large airway involvement

XXVIII.p Nasal, palatal and/or pharyngeal pathology

XXXI. Eye catchers

XXXI.h Midline destructive lesions

XXXVI. Autoimmune syndromes - Systemic reactions or conditions

XXXVI.s Dual MPO-/PR3-ANCA systemic disease/vasculitis or pseudovasculitis

XXXVI. Autoimmune syndromes - Systemic reactions or conditions

XXXVI.t Pneumorenal syndrome (w/wo ANCAs)

XXXVI. Autoimmune syndromes - Systemic reactions or conditions

XXXVI.u Pulmonary vasculitis or capillaritis

XXXVIII. Miscellaneous - Varia

XXXVIII.d Death following exposure or poisoning

XXXVIII. Miscellaneous - Varia

XXXVIII.q Myopathy-Myositis-Polymyositis

XXXVIII. Miscellaneous - Varia

XXXVIII.y Neutropenia, agranulocytosis (w/wo infection/sepsis)